Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medibuy.com

This article was originally published in The Gray Sheet

Executive Summary

Medical device business-to-business e-commerce firm's initial public offering is anticipated to consist of 13 mil. shares at $10-12 per share, according to an amended registration statement filed March 16 with the Securities and Exchange Commission. The amended prospectus also reflects the March 7 agreement to acquire Premier's medical products e-commerce company Premier Health Exchange (1"The Gray Sheet" March 13, p. 13). The proposed $130-156 mil. offering is about double the $75 mil. offering anticipated in a preliminary prospectus filed in January

You may also be interested in...



Medibuy.com Doubles Registered Buyers Via March 7 Premier Acquisition

Medibuy.com will file an amendment to its S-1 form in the next couple of weeks to reflect the March 7 agreement to acquire Premier's medical products e-commerce company, Premier Health Exchange.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT013123

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel